The half-life extended FcRn inhibitor showed a 74% peak reduction in IgG in healthy volunteers.
News|Articles|July 10, 2026
Prescription eye drops recalled nationwide by FDA
Author(s)Lynda Charters
The FDA issued a nationwide recall of a steroid eye drop.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) announced a nationwide recall of millions of bottles of prescription steroid eye drops because of the potential contamination by “a foreign substance,” according to the agency’s enforcement report.
Related to this article
The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.
Now on the company's EYE7 smart glasses platform, Eva is designed to go beyond answering questions about the visual environment by reasoning about user needs and directly controlling the device's vision-enhancement features.
The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.
Josef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.
The FDA adds a NAION warning to GLP-1 drugs, plus LEMS clues, Eyedaptic's new Eva AI assistant and a retinal imaging link to AFib.
The first-in-human study of the GalNAc-conjugated siRNA joins a fast-moving Stargardt pipeline as the FDA weighs the first potential approval for the disease.
The once-daily combination drop is approved by the FDA to treat presbyopia.
Advertisement
Advertisement